In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia
Journal of Cosmetic Dermatology · 2026
DOI: 10.1111/jocd.70686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2026. Verfasst von Ashish C Bhatia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Drug Delivery Systems, Serum. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ourself.
Abstract (Originalsprache)
Background/Aims Pigmentary problems are common and can arise from sun exposure, skin inflammation, changes in hormones, and certain medications. Because they are visible, these pigmentary problems can be very distressing for individuals, and they are often challenging to manage. Three studies were conducted, ex vivo, in vitro, and in vivo. Subjects/Methods An in vitro study of brightening/lightening in skin models; an ex vivo skin study using Raman spectroscopy; and a 12‐week clinical study of a novel complexion brightening serum with Tiered‐Release Vesicle (CBS‐TRV) delivery technology in adults with moderate to severe photodamage and uneven skin tone. Assessments included clinical grading, melanin and erythema measurements by Mexameter, digital imaging, and a patient self‐assessment questionnaire. Standard safety and tolerability assessments were also performed.
Results
The in vitro 3D skin study showed that a 2 μL/cm 2 application of CBS‐TRV (the recommended and clinical application volume) slowed melanin production by 37.5% compared to untreated tissues after 2 weeks. Furthermore, Raman spectroscopy provided evidence for tranexamic acid penetration into the epidermis of ex vivo human skin. Clinical grading revealed significant improvements at the majority of visits, which were accompanied by improvements of erythema index and melanin index on mexameter. In addition, subjects provided positive feedback regarding the clinical results as well as the formulation's aesthetics. Finally, the CBS‐TRV product was safe and well tolerated.
Conclusions
The multiple active ingredients in CBS‐TRV target melanogenesis in a variety of ways, and both in vitro and clinical studies demonstrated significant improvements in skin tone and pigmentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Dermatology, UC San Diego Health, San Diego, California, USA.
- Moradi MD/Private Practice, Vista, California, USA.
- Pacific Clinical Innovations/Clinical Research Site, Vista, California, USA.
- Ourself, Carlsbad, California, USA.
ORCID-Profile: Ashish C Bhatia, Tina Fleck
Förderung
- Ourself
Zitieren
APA
Bhatia, A. C., Ortiz, A., Kannan, S., Moradi, A., Fleck, T., Love, R., & Osborne, S. (2026). In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70686
Vancouver
Bhatia AC, Ortiz A, Kannan S, Moradi A, Fleck T, Love R, et al. In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia. Journal of Cosmetic Dermatology. 2026. doi:10.1111/jocd.70686
BibTeX
@article{Bhatia2026,
author = {Bhatia, Ashish C and Ortiz, Arisa and Kannan, Swati and Moradi, Amir and Fleck, Tina and Love, Robert and Osborne, Stacy},
title = {In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
doi = {10.1111/jocd.70686}
}
EUVIMED